Your session is about to expire
← Back to Search
Virus Therapy
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults
Phase 1
Waitlist Available
Research Sponsored by GlaxoSmithKline
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at month 7 (i.e. 5 months after the last vaccination)
Summary
This trial is testing a new rabies vaccine in healthy adults to see if it is safe and effective. The vaccine works by introducing a protein from the rabies virus to help the immune system recognize and fight the virus. Over two-thirds of the world's population lives in regions where rabies is common, resulting in over 15 million people receiving treatment after exposure and over 55,000 deaths per year globally.
Eligible Conditions
- Central Nervous System Viral Infection
- Viral Diseases
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at month 7 (i.e. 5 months after the last vaccination)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at month 7 (i.e. 5 months after the last vaccination)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of participants reporting medically attended AE (MAEs)
Number of participants reporting potential immune-mediated diseases (pIMDs)
Number of participants reporting serious adverse events (SAEs)
+12 moreSecondary study objectives
Evaluation of immunogenicity in terms of Anti-rabies G IgG antibody concentrations
Evaluation of immunogenicity in terms of Rabies Virus Neutralizing Antibody (RVNA) concentrations
Evaluation of persistence of immunogenicity in terms of anti-rabies G IgG antibody concentrations at 10 months after last vaccination
+8 moreTrial Design
6Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Medium dose (Md-) RG SAM (CNE) groupExperimental Treatment1 Intervention
Healthy adults,18 to 40 years of age, will receive one intramuscular injection of RG SAM (CNE) medium dose formulation vaccine in one arm and one intramuscular injection of saline solution in the opposite arm at Day 1.
Group II: Lowest dose (Ltd-) RG SAM (CNE) groupExperimental Treatment1 Intervention
Healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RG SAM (CNE) lowest dose formulation vaccine in one arm according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61)
Group III: Lower dose (Lrd-) RG SAM (CNE) groupExperimental Treatment1 Intervention
Healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RG SAM (CNE) lower dose formulation vaccine in one arm according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61)
Group IV: Low dose (Ld-) RG SAM (CNE) groupExperimental Treatment1 Intervention
In Part 1 of the study, healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RG SAM (CNE) low dose formulation vaccine in one arm and one intramuscular injection of saline solution in the opposite arm at Days 1 and 61).
In Part 2 of the study, healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RG SAM (CNE) low dose formulation vaccine in one arm according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61)
Group V: RabAvert groupActive Control1 Intervention
In Part 1 of the study, healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RabAvert in one arm and one intramuscular injection of saline solution in the other arm, according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61).
In Part 2 of the study, healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RabAvert in one arm according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61).
Group VI: Saline Placebo groupPlacebo Group1 Intervention
In Part 1 of the study, healthy adults, 18 to 40 years of age, will receive two intramuscular injections of saline placebo, one in each arm, according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61).
In Part 2 of the study, healthy adults, 18 to 40 years of age will receive one intramuscular injections of saline placebo in one arm according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lower dose formulation of RG SAM (CNE) vaccine (GSK3903133A)
2019
Completed Phase 1
~160
Lowest dose formulation of RG SAM (CNE) vaccine (GSK3903133A)
2019
Completed Phase 1
~160
Low dose formulation of RG SAM (CNE) vaccine (GSK3903133A)
2019
Completed Phase 1
~160
Medium dose formulation of RG SAM (CNE) vaccine (GSK3903133A)
2019
Completed Phase 1
~160
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
GlaxoSmithKlineLead Sponsor
4,812 Previous Clinical Trials
8,382,088 Total Patients Enrolled
GSK Clinical TrialsStudy DirectorGlaxoSmithKline (for GlaxoSmithKline; Human Genome Sciences Inc., a GSK Company; Sirtris, a GSK Company; Stiefel, a GSK Company; ViiV Healthcare)
3,605 Previous Clinical Trials
6,144,911 Total Patients Enrolled